88-LB: Kidney and Metabolic Benefits by Adding GLP-1 Agonists and/or SGLT2 Inhibitors on Metformin in Obese Type 2 Diabetes (T2DM) Patients: 24-Month Real-World Data from Both Urban and Rural Clinics

Objective: Assessment of the nephro-metabolic effects of GLP-1 agonists (Group A), SGLT-2 inhibitors (Group B) and both (Group C) in obese patients under metformin therapy with inadequate glycemic control. Materials and Methods: 253 patients with T2DM on metformin with a HbA1c > 7.0%. Results: Group A: reduction of HbA1c at 5.9±0.4% (95% C.I. of difference 1.63-3.03, p Conclusions: Triple combination therapy with metformin - GLP1-analog - SGLT2-inhibitor has the greatest effectiveness in weight loss and in improving liver biochemistry. The renal improvement seen with these drugs appears to be driven by a decrease in UACR for SGLT-2-inhibitors and an increase in eGFR for GLP1-analogues in this retrospective 24-month study. Disclosure I. Zoupas: None. A. Papazafiropoulou: None. M. Xenou: None. D. Lygnos: None. E. Fousteris: None.